![]() |
Multiple Sclerosis |
Free Subscription
1 Ann Neurol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Multiple Sclerosis is free of charge.
Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation
Dynamics in Multiple Sclerosis.
Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
PubMed
Abstract available
Extending the role of neurofilament light in multiple sclerosis beyond measuring
irreversible neurodegeneration.
Brain. 2025 Jun 9:awaf224. doi: 10.1093.
PubMed
First-line use of higher-efficacy disease-modifying therapies in multiple
sclerosis: Canadian consensus recommendations.
Can J Neurol Sci. 2025 Jun 9:1-28. doi: 10.1017/cjn.2025.10342.
PubMed
Retinal neuronal loss and progression independent of relapse activity in multiple
sclerosis.
J Neurol. 2025;272:454.
PubMed
Abstract available
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with
multiple sclerosis: definition of different patient archetypes from an Italian
expert group perspective.
J Neurol. 2025;272:446.
PubMed
Abstract available
Blood biomarkers for predicting disability worsening in progressive multiple
sclerosis: a multinational, individual participant-level analysis.
J Neurol Neurosurg Psychiatry. 2025 Jun 12:jnnp-2025-335831.
PubMed
Abstract available
Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple
sclerosis.
J Neurol Sci. 2025;475:123577.
PubMed
Abstract available
Impact of brain volume on coronavirus disease of 2019 severity and subsequent
cognitive decline in patients with multiple sclerosis.
J Neurol Sci. 2025;475:123552.
PubMed
Abstract available
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people
with multiple sclerosis.
J Neurol Sci. 2025;475:123562.
PubMed
Abstract available
Safety assessment of switching from fingolimod to siponimod: An Italian
multicenter prospective study.
J Neurol Sci. 2025;474:123533.
PubMed
Abstract available
Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
PubMed
Abstract available
Erratum: Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying
Therapies: A Real-World Pharmacovigilance Study.
Neurol Clin Pract. 2025;15:e200505.
PubMed
Abstract available
Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis.
Neurol Clin Pract. 2025;15:e200493.
PubMed
Abstract available
Editorial Expression of Concern for Poon et al., Targeting the muscarinic M1
receptor with a selective, brain-penetrant antagonist to promote remyelination in
multiple sclerosis.
Proc Natl Acad Sci U S A. 2025;122:e2512750122.
PubMed
Data linkage between the French multiple sclerosis cohort (OFSEP) and the French
national health insurance database (SNDS).
Rev Neurol (Paris). 2025 Jun 5:S0035-3787(25)00537.
PubMed
Abstract available
Thank you for your interest in scientific medicine.